<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article
  PUBLIC "-//NLM//DTD Journal Publishing DTD v2.3 20070202//EN" "journalpublishing.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article">
<front>
<journal-meta>
<journal-id journal-id-type="publisher-id">CPR</journal-id>
<journal-id journal-id-type="hwp">spcpr</journal-id>
<journal-title>European Journal of Preventive Cardiology</journal-title>
<issn pub-type="ppub">2047-4873</issn>
<issn pub-type="epub">2047-4881</issn>
<publisher>
<publisher-name>SAGE Publications</publisher-name>
<publisher-loc>Sage UK: London, England</publisher-loc>
</publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="doi">10.1177/1741826711400511</article-id>
<article-id pub-id-type="publisher-id">10.1177_1741826711400511</article-id>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Myocardial infarction</subject>
<subj-group subj-group-type="heading">
<subject>Original scientific paper</subject>
</subj-group>
</subj-group>
</article-categories>
<title-group>
<article-title>Gender-related difference in ST-elevation myocardial infarction treated with primary angioplasty: a single-centre 6-year registry</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author" corresp="yes">
<name><surname>Valente</surname><given-names>Serafina</given-names></name>
<xref ref-type="corresp" rid="corresp1-1741826711400511"/>
</contrib>
<contrib contrib-type="author">
<name><surname>Lazzeri</surname><given-names>Chiara</given-names></name>
</contrib>
<contrib contrib-type="author">
<name><surname>Chiostri</surname><given-names>Marco</given-names></name>
</contrib>
<contrib contrib-type="author">
<name><surname>Giglioli</surname><given-names>Cristina</given-names></name>
</contrib>
<contrib contrib-type="author">
<name><surname>Zucchini</surname><given-names>Mery</given-names></name>
</contrib>
<contrib contrib-type="author">
<name><surname>Grossi</surname><given-names>Francesco</given-names></name>
</contrib>
<contrib contrib-type="author">
<name><surname>Gensini</surname><given-names>Gian Franco</given-names></name>
</contrib>
</contrib-group>
<aff id="aff1-1741826711400511">Intensive Cardiac Care Unit, Heart and Vessel Department, Azienda Ospedaliero-Universitaria Careggi, Florence, Italy.</aff>
<author-notes>
<corresp id="corresp1-1741826711400511">Serafina Valente, Heart and Vessel Department, Viale Morgagni 85, 50134 Florence, Italy Email: <email>seravalente@hotmail.com</email></corresp>
</author-notes>
<pub-date pub-type="epub-ppub">
<month>4</month>
<year>2012</year>
</pub-date>
<volume>19</volume>
<issue>2</issue>
<fpage>233</fpage>
<lpage>240</lpage>
<history>
<date date-type="received"><day>30</day><month>9</month><year>2010</year></date>
<date date-type="accepted"><day>22</day><month>1</month><year>2011</year></date>
</history>
<permissions>
<copyright-statement>© The European Society of Cardiology 2011 Reprints and permissions: sagepub.co.uk/journalsPermissions.nav</copyright-statement>
<copyright-year>2011</copyright-year>
<copyright-holder content-type="society">European Society of Cardiology</copyright-holder>
</permissions>
<abstract>
<p><bold>Objective:</bold> Still contrasting are data on the impact of sex on outcome in patients with ST-elevation myocardial infarction (STEMI) treated with percutaneous coronary intervention (PCI).</p>
<p><bold>Design:</bold> We sought sex-related differences in management and early outcomes in 1127 STEMI patients submitted to PCI consecutively admitted to our intensive cardiac care unit (ICCU) in Florence from 1 January 2004 to 31 December 2009.</p>
<p><bold>Results:</bold> Females were significantly older, leaner (<italic>p</italic> &lt; 0.001, respectively), more hypertensive (<italic>p</italic> &lt; 0.001), and diabetic (<italic>p</italic> = 0.016); they showed a higher incidence of neurological impairment (<italic>p</italic> = 0.002) and chronic obstructive pulmonary disease (<italic>p</italic> = 0.048). Higher Killip classes were more frequent in females (<italic>p</italic> = 0.015). Door-to-balloon time was higher in females (<italic>p</italic> &lt; 0.001) who showed a higher incidence of major bleeding (<italic>p</italic> &lt; 0.001) and a higher in-ICCU mortality rate (<italic>p</italic> = 0.037). The use of IIbIIIa glycoprotein inhibitors was lower in females (<italic>p</italic> &lt; 0.001) who exhibited higher values of admission glycaemia and peak glycaemia (<italic>p</italic> &lt; 0.001 and <italic>p</italic> &lt; 0.001, respectively), higher values of fibrinogen (<italic>p</italic> &lt; 0.001) and erythrocyte sedimentation rate (<italic>p</italic> &lt; 0.001), and lower eGFR and haemoglobin values (<italic>p</italic> &lt; 0.001).</p>
<p><bold>Conclusions:</bold> According to our data, STEMI women show not only a different risk profile (older age, comorbidities, lower haemoglobin values), but also a different gender-related metabolic and inflammatory responses to acute myocardial ischaemia in respect to men. All these factors can account for the higher in-ICCU mortality in women and strongly suggest that STEMI women deserve more intensive care due to a more severe haemodynamic derangement (as indicated by the higher use of inotropes, diuretics, and non-invasive ventilation) and to a more serious metabolic impairment (as inferred by higher glucose values).</p>
</abstract>
<kwd-group>
<kwd>Female gender</kwd>
<kwd>major bleeding</kwd>
<kwd>mortality</kwd>
<kwd>metabolic and inflammatory responses</kwd>
<kwd>PCI</kwd>
<kwd>ST-elevation myocardial infarction</kwd>
</kwd-group>
</article-meta>
</front>
<body>
<sec id="sec1-1741826711400511" sec-type="intro"><title>Introduction</title>
<p>Despite the advances in treatment for acute ST-elevation myocardial infarction (STEMI) during the past decades, most previous studies reported on significantly higher unadjusted in-hospital and long-term mortality rates among women compared with men.<sup><xref ref-type="bibr" rid="bibr1-1741826711400511">1</xref></sup><sup>–</sup><sup><xref ref-type="bibr" rid="bibr4-1741826711400511">4</xref></sup> However, the association of gender, quality of care, metabolic and inflammatory profiles, and clinical outcomes has not been specifically assessed in STEMI patients submitted to percutaneous coronary intervention (PCI).</p>
<p>In the present investigation we sought sex-related differences in management and early outcomes in 1127 STEMI patients treated with PCI consecutively admitted to our intensive cardiac care unit (ICCU) in Florence from 1 January 2004 to 31 December 2009.</p>
</sec>
<sec id="sec2-1741826711400511" sec-type="methods"><title>Methods</title>
<sec id="sec3-1741826711400511"><title>Study population</title>
<p>We analysed data from 1127 consecutive patients with STEMI (within 12 hours from symptoms’ onset) enrolled, from 1 January 2004 to 31 December 2009, in a prospective registry conducted at our ICCU, which is located at a tertiary centre. STEMI patients with normal coronary angiography or not submitted to primary PCI were excluded from the study.</p>
<p>In our hospital, in Florence, the reperfusion strategy of STEMI patients is represented by primary PCI.<sup><xref ref-type="bibr" rid="bibr5-1741826711400511">5</xref>,<xref ref-type="bibr" rid="bibr6-1741826711400511">6</xref></sup> Patients are first evaluated by the medical emergency system staff in the pre-hospital setting and then directly admitted to the catheterization laboratory or transferred to it after a rapid stabilization in first aid. After primary PCI, they are admitted to our ICCU.</p>
<p>A successful procedure was defined as a post-procedure infarct stenosis &lt;20% associated with TIMI (thrombolysis in myocardial infarction) grade 3 flow. Failure PCI was defined as resulting in TIMI grade 0–2 flow, regardless the residual stenosis.<sup><xref ref-type="bibr" rid="bibr6-1741826711400511">6</xref></sup> The diagnosis of STEMI was based on the criteria of the American College of Cardiology/American Heart Association.<sup><xref ref-type="bibr" rid="bibr5-1741826711400511">5</xref></sup></p>
<p>On ICCU admission, after PCI, in a fasting blood sample the following parameters were measured: glucose (g/l), troponin I (ng/ml), uric acid (mg/dl), NT-pro brain natriuretic peptide (NT-BNP) (pg/ml), leukocyte count (×10<sup>3</sup>/µl), platelet count (×10<sup>3</sup>/µl), admission haemoglobin (g/l) fibrinogen (mg/dl), erythrocyte sedimentation rate (ESR), glycated haemoglobin (%), cholesterol (mg/dl) and triglycerides (mg/dl), and C-reactive protein (normal values: &lt;9.0 mg/dl). Creatinine (mg/dl) was also measured in order to calculate glomerular filtration rate (ml/min/1.73 m<sup>2</sup>). Glucose values and troponin I (TnI) were measured three times a day throughout ICCU stay and peak glucose<sup><xref ref-type="bibr" rid="bibr7-1741826711400511">7</xref></sup> and peak TnI were considered,<sup><xref ref-type="bibr" rid="bibr6-1741826711400511">6</xref>,<xref ref-type="bibr" rid="bibr7-1741826711400511">7</xref></sup> respectively.</p>
<p>Transthoracic 2-dimensional echocardiography was performed in order to measure left ventricular ejection fraction (LVEF).</p>
</sec>
<sec id="sec4-1741826711400511"><title>Primary outcomes were in-ICCU mortality and major bleeding</title>
<p>Major bleeding was defined according to TIMI-1 classification as follows:<sup><xref ref-type="bibr" rid="bibr8-1741826711400511">8</xref></sup> intracranial haemorrhage or a ≥5 g/dl decrease in the haemoglobin concentration or a ≥15% absolute decrease in the hematocrit.</p>
</sec>
<sec id="sec5-1741826711400511"><title>Statistical analysis</title>
<p>Data have been processed by means of SPSS 13.0 statistical package (SPSS Inc, Chicago, IL). A <italic>p</italic>-value &lt;0.05 was considered statistically significant. Data are reported as frequencies (percentages) and median (95% CI) and analysed by means of χ<sup>2</sup> (or Fisher’s exact text, when appropriate) and Mann–Whitney <italic>U</italic>-test, respectively. Univariable and multivariable logistic regression analyses were carried out considering as outcomes intra-ICCU mortality and major bleedings. In multivariate analysis, candidate predictors were, among all variables collected in our database, those resulted unadjusted predictors for early mortality and for major bleedings, respectively. In these two models we considered, on the basis of their statistical significance (as inferred from Wald’s statistic), variables exploring clinical aspects. Gender was forced in both models.</p>
</sec>
</sec>
<sec id="sec6-1741826711400511" sec-type="results"><title>Results</title>
<p>Baseline characteristics are depicted in <xref ref-type="table" rid="table1-1741826711400511">Table 1</xref>. Our series mainly comprises males (73.8%). Females were significantly older, leaner (both <italic>p</italic> &lt; 0.001), more hypertensive (<italic>p</italic> &lt; 0.001), and diabetic (<italic>p</italic> = 0.016); they showed a higher incidence of neurological impairment (<italic>p</italic> = 0.002) and chronic obstructive pulmonary disease (<italic>p</italic> = 0.048). Smoking was more frequent in males (<italic>p</italic> &lt; 0.001). No gender difference was detectable in myocardial infarction location, while higher Killip classes were more frequent in females (<italic>p</italic> = 0.015). Latency was higher in females (<italic>p</italic> &lt; 0.001) who showed a higher incidence of major bleeding (<italic>p</italic> &lt; 0.001) and were administered more transfusions (<italic>p</italic> = 0.005). A higher in-ICCU mortality rate (<italic>p</italic> = 0.037) was observed in females.
<table-wrap id="table1-1741826711400511" position="float"><label>Table 1.</label><caption><p>Clinical characteristics</p></caption>
<graphic alternate-form-of="table1-1741826711400511" xlink:href="10.1177_1741826711400511-table1.tif"/>
<table frame="hsides"><thead align="left">
<tr><th>Characteristic</th>
<th>All (<italic>n</italic> = 1127)</th>
<th>Males (<italic>n</italic> = 832, 73.8%)</th>
<th>Females (<italic>n</italic> = 295, 26.2%)</th>
<th><italic>p</italic>-value (Mann–Whitney <italic>U</italic> or χ<sup>2</sup>)</th></tr></thead>
<tbody align="left">
<tr>
<td>Age (years)</td>
<td>67 (58–77)</td>
<td>65 (56–74)</td>
<td>76 (66–81)</td>
<td>&lt;0.001</td></tr>
<tr>
<td>BMI (kg/m<sup>2</sup>)</td>
<td>26.0 (23.7–28.1)</td>
<td>26.0 (24.1–28.3)</td>
<td>25.4 (22.7–27.6)</td>
<td>&lt;0.001</td></tr>
<tr>
<td>Hypertension</td>
<td>602 (53.4)</td>
<td>416 (50.2)</td>
<td>186 (63.7)</td>
<td>&lt;0.001</td></tr>
<tr>
<td>Diabetes</td>
<td>290 (25.7)</td>
<td>199 (24.0)</td>
<td>91 (31.2)</td>
<td>0.016</td></tr>
<tr>
<td>Dyslipidaemia</td>
<td>405 (35.9)</td>
<td>295 (35.6)</td>
<td>110 (37.7)</td>
<td>0.523</td></tr>
<tr>
<td>Smoke</td>
<td>699 (62.0)</td>
<td>593 (71.5)</td>
<td>106 (36.2)</td>
<td>&lt;0.001</td></tr>
<tr>
<td>POA</td>
<td>52 (4.6)</td>
<td>34 (4.1)</td>
<td>18 (6.1)</td>
<td>0.156</td></tr>
<tr>
<td>Neurological impairment</td>
<td>54 (4.8)</td>
<td>30 (3.6)</td>
<td>24 (8.1)</td>
<td>0.002</td></tr>
<tr>
<td>Chronic renal failure</td>
<td>50 (4.4)</td>
<td>34 (4.1)</td>
<td>16 (5.4)</td>
<td>0.340</td></tr>
<tr>
<td>COPD</td>
<td>95 (8.4)</td>
<td>62 (7.5)</td>
<td>33 (11.2)</td>
<td>0.048</td></tr>
<tr>
<td>Previous AMI</td>
<td>161 (14.3)</td>
<td>128 (15.4)</td>
<td>33 (11.2)</td>
<td>0.076</td></tr>
<tr>
<td>Previous angina</td>
<td>284 (25.2)</td>
<td>214 (25.8)</td>
<td>70 (23.7)</td>
<td>0.492</td></tr>
<tr>
<td>Previous PCI</td>
<td>155 (13.8)</td>
<td>121 (14.6)</td>
<td>34 (11.5)</td>
<td>0.194</td></tr>
<tr>
<td>Previous CABG</td>
<td>25 (2.2)</td>
<td>19 (2.3)</td>
<td>6 (2.0)</td>
<td>0.800</td></tr>
<tr>
<td>Killip class</td>
<td/>
<td/>
<td/>
<td>0.015</td></tr>
<tr>
<td> I</td>
<td>898 (79.7)</td>
<td>681 (82.4)</td>
<td>217 (74.1)</td>
<td/></tr>
<tr>
<td> II</td>
<td>100 (8.9)</td>
<td>67 (8.1)</td>
<td>33 (11.2)</td>
<td/></tr>
<tr>
<td> III</td>
<td>35 (3.1)</td>
<td>21 (2.5)</td>
<td>14 (4.8)</td>
<td/></tr>
<tr>
<td> IV</td>
<td>94 (8.3)</td>
<td>63 (7.5)</td>
<td>31 (10.5)</td>
<td/></tr>
<tr>
<td>AMI location</td>
<td/>
<td/>
<td/>
<td>0.342</td></tr>
<tr>
<td> Inferior</td>
<td>429 (38.1)</td>
<td>327 (39.3)</td>
<td>102 (34.6)</td>
<td/></tr>
<tr>
<td> Lateral</td>
<td>90 (8.0)</td>
<td>64 (7.7)</td>
<td>26 (8.8)</td>
<td/></tr>
<tr>
<td> Anterior</td>
<td>608 (53.9%</td>
<td>441 (53.0)</td>
<td>167 (56.6)</td>
<td/></tr>
<tr>
<td>Latency (min)</td>
<td>240 (160–330)</td>
<td>210 (150–300)</td>
<td>240 (180–374)</td>
<td>&lt;0.001</td></tr>
<tr>
<td>In-ICCU outcomes</td>
<td/>
<td/>
<td/>
<td/></tr>
<tr>
<td> Major bleeding</td>
<td>98 (8.6)</td>
<td>58 (7.0)</td>
<td>40 (13.6)</td>
<td>&lt;0.001</td></tr>
<tr>
<td> Blood transfusion</td>
<td>72 (6.4)</td>
<td>43 (5.2)</td>
<td>29 (9.8)</td>
<td>0.005</td></tr>
<tr>
<td> Death</td>
<td>58 (5.1)</td>
<td>36 (4.3)</td>
<td>22 (7.5)</td>
<td>0.037</td></tr>
</tbody>
</table>
<table-wrap-foot>
<fn id="table-fn1-1741826711400511"><p>Values are median (95% CI) or <italic>n</italic> (%).</p></fn>
<fn id="table-fn2-1741826711400511"><p>AMI, acute myocardial infarction; BMI, body mass index; CABG, coronary artery by-pass graft; COPD, chronic obstructive pulmonary disease; ICCU, intensive cardiac care unit; PCI, percutaneous coronary intervention; POA, peripheral obliterans arteriopathy.</p></fn></table-wrap-foot>
</table-wrap></p>
<p><xref ref-type="table" rid="table2-1741826711400511">Table 2</xref> shows the angiographic data in our population. No significant gender differences were observed in the extent of coronary artery disease, TIMI flow pre- and infarct related artery. In our series, bare metal stents were more frequently implanted in females (<italic>p</italic> &lt; 0.001), while drug-eluting stent in males (<italic>p</italic> = 0.002).The incidence of PCI failure was higher in females (<italic>p</italic> = 0.033) who exhibited lower left ventricular ejection fraction (<italic>p</italic> = 0.001). The use of IIbIIIa glycoprotein inhibitor was lower in females (<italic>p</italic> &lt; 0.001) while no gender difference was detectable in the administration of clopidogrel (loading doses), unfractioned heparin, and low-weight molecular heparin.
<table-wrap id="table2-1741826711400511" position="float"><label>Table 2.</label><caption><p>Angiographic data</p></caption>
<graphic alternate-form-of="table2-1741826711400511" xlink:href="10.1177_1741826711400511-table2.tif"/>
<table frame="hsides"><thead align="left">
<tr><th>Characteristic</th>
<th>Males (<italic>n</italic> = 832, 73.8%)</th>
<th>Females (<italic>n</italic> = 295, 26.2%)</th>
<th><italic>p</italic>-value (Mann–Whitney <italic>U</italic> or χ<sup>2</sup>)</th></tr></thead>
<tbody align="left">
<tr>
<td>Coronary artery disease</td>
<td/>
<td/>
<td>0.067</td></tr>
<tr>
<td> 1-vessel</td>
<td>307 (36.8)</td>
<td>133 (45.1)</td>
<td/></tr>
<tr>
<td> 2-vessel</td>
<td>300 (36.1)</td>
<td>87 (29.5)</td>
<td/></tr>
<tr>
<td> 3-vessel</td>
<td>225 (27.0)</td>
<td>75 (25.4)</td>
<td/></tr>
<tr>
<td>CABG</td>
<td>14 (1.7)</td>
<td>2 (0.7)</td>
<td>0.209</td></tr>
<tr>
<td>Left main</td>
<td>65 (7.9)</td>
<td>19 (6.5)</td>
<td>0.445</td></tr>
<tr>
<td>TIMI flow pre-PCI</td>
<td/>
<td/>
<td>0.728</td></tr>
<tr>
<td> III</td>
<td>13 (1.5)</td>
<td>6 (2.1)</td>
<td/></tr>
<tr>
<td> II</td>
<td>76 (9.2)</td>
<td>32 (11.0)</td>
<td/></tr>
<tr>
<td> I</td>
<td>140 (16.9)</td>
<td>52 (17.9)</td>
<td/></tr>
<tr>
<td> 0</td>
<td>603 (72.4)</td>
<td>205 (69.1)</td>
<td/></tr>
<tr>
<td>IRA</td>
<td/>
<td/>
<td>0.483</td></tr>
<tr>
<td> RCA</td>
<td>280 (33.6)</td>
<td>87 (29.5)</td>
<td/></tr>
<tr>
<td> CX</td>
<td>108 (13.0)</td>
<td>39 (13.2)</td>
<td/></tr>
<tr>
<td> DA</td>
<td>426 (51.2)</td>
<td>164 (55.6)</td>
<td/></tr>
<tr>
<td> Left main</td>
<td>9 (1.1)</td>
<td>4 (1.4)</td>
<td/></tr>
<tr>
<td> CABG</td>
<td>9 (1.1)</td>
<td>1 (0.3)</td>
<td/></tr>
<tr>
<td>Stent implantation</td>
<td>739 (88.8)</td>
<td>264 (89.8)</td>
<td>0.752</td></tr>
<tr>
<td>No stent</td>
<td>93 (11.2)</td>
<td>30 (10.2)</td>
<td>NS</td></tr>
<tr>
<td>BMS</td>
<td>364 (43.7)</td>
<td>163 (55.3)</td>
<td>&lt;0.001</td></tr>
<tr>
<td>DES</td>
<td>375 (45.1)</td>
<td>102 (34.5)</td>
<td>0.002</td></tr>
<tr>
<td>TIMI flow post-PCI</td>
<td/>
<td/>
<td>0.139</td></tr>
<tr>
<td> III</td>
<td>789 (94.8)</td>
<td>269 (91.1)</td>
<td/></tr>
<tr>
<td> II</td>
<td>28 (3.4)</td>
<td>15 (5.2)</td>
<td/></tr>
<tr>
<td> I</td>
<td>7 (0.9)</td>
<td>5 (1.7)</td>
<td/></tr>
<tr>
<td> 0</td>
<td>8 (1.0)</td>
<td>6 (2.1)</td>
<td/></tr>
<tr>
<td>PCI failure</td>
<td>43 (5.4)</td>
<td>26 (8.9)</td>
<td>0.033</td></tr>
<tr>
<td>IIbIIIa GI</td>
<td>608 (73.1)</td>
<td>173 (58.6)</td>
<td>&lt;0.001</td></tr>
<tr>
<td>Clopidogrel</td>
<td/>
<td/>
<td>0.087</td></tr>
<tr>
<td> 300 mg</td>
<td>503 (67.9)</td>
<td>197 (73.5)</td>
<td/></tr>
<tr>
<td> 600 mg</td>
<td>238 (32.1)</td>
<td>71 (26.5)</td>
<td/></tr>
<tr>
<td>UFH</td>
<td>699 (86.3)</td>
<td>251 (86.9)</td>
<td>0.813</td></tr>
<tr>
<td>LMWH</td>
<td>674 (85.8)</td>
<td>242 (84.6)</td>
<td>0.641</td></tr>
<tr>
<td>LVEF (%) median</td>
<td>45.0 (38.0–51.0)</td>
<td>43.0 (35.0–50.0)</td>
<td>0.001</td></tr>
</tbody>
</table>
<table-wrap-foot>
<fn id="table-fn3-1741826711400511"><p>Values are <italic>n</italic> (%) or median (95% CI).</p></fn>
<fn id="table-fn4-1741826711400511"><p>BMS, bare metal stent; CABG, coronary artery by-pass graft; CX, circumflex coronary artery; DA, descending anterior; DES, drug-eluting stent; GI, glycoprotein inhibitor; IRA, infarct related artery; LMWH, low molecular heparin; LVEF, left ventricular ejection fraction; PCI, percutaneous coronary intervention; RCA, right coronary artery; TIMI, thrombolysis in myocardial infarction; UFH, unfractionated heparin.</p></fn></table-wrap-foot>
</table-wrap></p>
<p>As shown in <xref ref-type="table" rid="table3-1741826711400511">Table 3</xref>, females exhibited higher values of admission glycaemia, peak glycaemia (both <italic>p</italic> &lt; 0.001), total cholesterol (<italic>p</italic> &lt; 0.001), and NT-proBNP (<italic>p</italic> &lt; 0.001) while levels of uric acid were lower (<italic>p</italic> = 0.032). Males showed lower values of fibrinogen (<italic>p</italic> &lt; 0.001), ESR (<italic>p</italic> &lt; 0.001), and platelet count (<italic>p</italic> &lt; 0.001), while no difference was observed in C-RP positivity. eGFR was lower in females who showed lower values of haemoglobin (<italic>p</italic> &lt; 0.001) and triglycerides (<italic>p</italic> = 0.001).
<table-wrap id="table3-1741826711400511" position="float"><label>Table 3.</label><caption><p>Laboratory data</p></caption>
<graphic alternate-form-of="table3-1741826711400511" xlink:href="10.1177_1741826711400511-table3.tif"/>
<table frame="hsides"><thead align="left">
<tr><th>Characteristic</th>
<th>Males (<italic>n</italic> = 832, 73.8%)</th>
<th>Females (<italic>n</italic> = 295, 26.2%)</th>
<th><italic>p</italic>-value (Mann–Whitney <italic>U</italic> or χ<sup>2</sup>)</th></tr></thead>
<tbody align="left">
<tr>
<td>Admission glycaemia (mg/dl)</td>
<td>1.28 (1.10–1.63)</td>
<td>1.45 (1.20–1.93)</td>
<td>&lt;0.001</td></tr>
<tr>
<td>Peak glycaemia (mg/dl)</td>
<td>1.48 (1.25–1.89)</td>
<td>1.72 (1.39–2.21)</td>
<td>&lt;0.001</td></tr>
<tr>
<td>Glycated Hb &gt;6.5%</td>
<td>109 (21.0)</td>
<td>52 (26.5)</td>
<td>0.114</td></tr>
<tr>
<td>Uric acid (mg/dl)</td>
<td>5.6 (4.6–6.7)</td>
<td>5.4 (4.0–6.6)</td>
<td>0.032</td></tr>
<tr>
<td>NT-pro-BNP (pg/ml)</td>
<td>1015 (403–2336)</td>
<td>3035 (1185–7825)</td>
<td>&lt;0.001</td></tr>
<tr>
<td>Cholesterol (mg/dl)</td>
<td>183 (154–210)</td>
<td>195 (162–222)</td>
<td>&lt;0.001</td></tr>
<tr>
<td>Tryglycerides (mg/dl)</td>
<td>104 (78–145)</td>
<td>92 (70–129)</td>
<td>0.001</td></tr>
<tr>
<td>Peak TnI (ng/ml)</td>
<td>82.4(37.9–174.4)</td>
<td>83.0 (36.0–188.4)</td>
<td>0.675</td></tr>
<tr>
<td>Fibrinogen (mg/dl)</td>
<td>380 (323–462)</td>
<td>422 (360–507)</td>
<td>&lt;0.001</td></tr>
<tr>
<td>Leucocytes (×10<sup>3</sup>/ml)</td>
<td>10.9 (9.0–13.8)</td>
<td>10.9 (8.8–14.0)</td>
<td>0.647</td></tr>
<tr>
<td>ESR (mm/h)</td>
<td>22 (12–37)</td>
<td>34 (19–49)</td>
<td>&lt;0.001</td></tr>
<tr>
<td>CRP positivity</td>
<td>336 (49.1)</td>
<td>134 (54.5)</td>
<td>0.150</td></tr>
<tr>
<td>eGFR (ml/min/1.73 m<sup>2</sup>)</td>
<td>80.6 (67.0–95.9)</td>
<td>71.1 (50.4–89.0)</td>
<td>&lt;0.001</td></tr>
<tr>
<td>Admission Hb (g/dl)</td>
<td>14.0 (13.0–14.8)</td>
<td>12.7 (11.4–13.8)</td>
<td>&lt;0.001</td></tr>
<tr>
<td>PLT(×10<sup>3</sup>/ml)</td>
<td>209 (172–250)</td>
<td>225 (190–276)</td>
<td>&lt;0.001</td></tr>
</tbody>
</table>
<table-wrap-foot>
<fn id="table-fn5-1741826711400511"><p>Values are <italic>n</italic> (%) or median (95% CI).</p></fn>
<fn id="table-fn6-1741826711400511"><p>CRP, C-reactive protein; eGFR, estimated glomerular filtration rate; ESR, erythrocyte sedimentation rate; Hb, haemoglobin; NT-pro-BNP, N-terminal pro-brain natriuretic peptide; PLT, platelet; TnI, troponin I.</p></fn></table-wrap-foot>
</table-wrap></p>
<p>During ICCU-stay (<xref ref-type="table" rid="table4-1741826711400511">Table 4</xref>), statins were more frequently administered to males (<italic>p</italic> = 0.039) whereas the use of diuretics and inotropes was higher in females (<italic>p</italic> = 0.006, <italic>p</italic> = 0.002, respectively). No gender difference was observed in antiplatelet therapy. Non-invasive ventilation was more frequently used in females (≥0.043).
<table-wrap id="table4-1741826711400511" position="float"><label>Table 4.</label><caption><p>Drug regimens and devices during ICCU stay</p></caption>
<graphic alternate-form-of="table4-1741826711400511" xlink:href="10.1177_1741826711400511-table4.tif"/>
<table frame="hsides"><thead align="left">
<tr><th>In-ICCU treatment</th>
<th>Males (<italic>n</italic> = 832, 73.8%)</th>
<th>Females (<italic>n</italic> = 295, 26.2%)</th>
<th><italic>p</italic>-value (Mann–Whitney <italic>U</italic> or χ<sup>2</sup>)</th></tr></thead>
<tbody align="left">
<tr>
<td colspan="4">Medications</td></tr>
<tr>
<td> ACE-inhibitors</td>
<td>749 (91.1)</td>
<td>255 (87.3)</td>
<td>0.062</td></tr>
<tr>
<td> ARB</td>
<td>16 (2.0)</td>
<td>7 (2.4)</td>
<td>0.650</td></tr>
<tr>
<td> Beta-blockers</td>
<td>693 (84.2)</td>
<td>237 (80.9)</td>
<td>0.191</td></tr>
<tr>
<td> Calcium channel blockers</td>
<td>32 (3.9)</td>
<td>14 (4.8)</td>
<td>0.506</td></tr>
<tr>
<td> Diuretics</td>
<td>586 (71.2)</td>
<td>233 (79.5)</td>
<td>0.006</td></tr>
<tr>
<td> Statins</td>
<td>766 (93.2)</td>
<td>262 (89.4)</td>
<td>0.039</td></tr>
<tr>
<td> Aspirin</td>
<td>806 (97.3)</td>
<td>281 (95.3)</td>
<td>0.080</td></tr>
<tr>
<td> Clopidogrel</td>
<td>805 (97.2)</td>
<td>284 (96.3)</td>
<td>0.413</td></tr>
<tr>
<td> Inotropes</td>
<td>101 (24.0)</td>
<td>58 (36.9)</td>
<td>0.002</td></tr>
<tr>
<td> Dopamine</td>
<td>82 (11.6)</td>
<td>52 (20.4)</td>
<td>&lt;0.001</td></tr>
<tr>
<td> Dopamine max (mcg/kg/min)</td>
<td>8 (4.8–8.5)</td>
<td>8.0 (7.0–8.5)</td>
<td>0.162</td></tr>
<tr>
<td> Dobutamine</td>
<td>27 (3.8)</td>
<td>15 (5.9)</td>
<td>0.168</td></tr>
<tr>
<td> Dobutamine max (mcg//kg/min)</td>
<td>3.3 (2.3–5.0)</td>
<td>2.5 (2.0–3.5)</td>
<td>0.626</td></tr>
<tr>
<td> Epinephrine</td>
<td>22 (2.8)</td>
<td>18 (6.3)</td>
<td>0.007</td></tr>
<tr>
<td> Epinephrine max (mcg//kg/min)</td>
<td>0.50 (0.06–1.00)</td>
<td>0.20 (0.08–0.50)</td>
<td>0.805</td></tr>
<tr>
<td> Norepinephrine</td>
<td>31 (4.4)</td>
<td>21 (8.2)</td>
<td>0.020</td></tr>
<tr>
<td> Norepinephrine max (mcg//kg/min)</td>
<td>0.65 (0.24–0.90)</td>
<td>0.28 (0.10–0.60)</td>
<td>0.266</td></tr>
<tr>
<td colspan="4">Devices</td></tr>
<tr>
<td> CVVHDF</td>
<td>31 (3.8)</td>
<td>14 (4.8)</td>
<td>0.451</td></tr>
<tr>
<td> Mechanical ventilation</td>
<td>61 (7.4)</td>
<td>28 (9.7)</td>
<td>0.218</td></tr>
<tr>
<td> cPAP</td>
<td>41 (5.2)</td>
<td>24 (8.6)</td>
<td>0.043</td></tr>
<tr>
<td> IABP</td>
<td>199 (24.4)</td>
<td>85 (29.5)</td>
<td>0.091</td></tr>
</tbody>
</table>
<table-wrap-foot>
<fn id="table-fn7-1741826711400511"><p>Values are <italic>n</italic> (%) or median (95% CI).</p></fn>
<fn id="table-fn8-1741826711400511"><p>cPAP, continuous positive airway pressure; CVVHDF, continuous veno-venous haemo-dia filtration; IABP, intra-aortic balloon pump; ICCU, intensive cardiac care unit.</p></fn></table-wrap-foot>
</table-wrap></p>
<sec id="sec7-1741826711400511"><title>Multivariable logistic regression analysis</title>
<p><xref ref-type="table" rid="table5-1741826711400511">Table 5</xref> depicts multivariate logistic regression analysis for both in-ICCU mortality and major bleedings. Gender did not reach statistical significance.
<table-wrap id="table5-1741826711400511" position="float"><label>Table 5.</label><caption><p>Multivariate logistic regression analysis</p></caption>
<graphic alternate-form-of="table5-1741826711400511" xlink:href="10.1177_1741826711400511-table5.tif"/>
<table frame="hsides"><thead align="left">
<tr><th rowspan="2">Variable</th>
<th colspan="3">Outcome: In-ICCU death<hr/></th></tr>
<tr><th>Odds ratio</th>
<th>95% CI</th>
<th><italic>p</italic>-value</th></tr></thead>
<tbody align="left">
<tr>
<td>Gender (male vs. female)</td>
<td>0.542</td>
<td>0.586 to 2.768</td>
<td>0.542</td></tr>
<tr>
<td>Age (1 year step)</td>
<td>1.041</td>
<td>1.002 to 1.081</td>
<td>0.038</td></tr>
<tr>
<td>PCI failure (yes vs. no)</td>
<td>5.253</td>
<td>2.266 to 12.18</td>
<td>&lt;0.001</td></tr>
<tr>
<td>LVEF (1% step)</td>
<td>0.932</td>
<td>0.900 to 0.965</td>
<td>&lt;0.001</td></tr>
<tr>
<td>Adm. glycaemia (1 g/l step)</td>
<td>2.186</td>
<td>1.504 to 3.176</td>
<td>&lt;0.001</td></tr>
<tr>
<td>Adm. eGFR (1 ml/min/1.73 m<sup>2</sup> step)</td>
<td>0.985</td>
<td>0.971 to 0.999</td>
<td>0.033</td></tr>
<tr>
<td>Peak TnI (10 pg/ml step)</td>
<td>1.021</td>
<td>1.009 to 1.034</td>
<td>&lt;0.001</td></tr>
<tr>
<td colspan="4">Hosmer-Lemeshow goodness-of-fit χ<sup>2</sup> = 8.86, <italic>p</italic> = 0.354. Nagelkerke R<sup>2 </sup>= 0.42.</td></tr>
<tr>
<td/>
<td colspan="3">Outcome: major bleeding<hr/></td></tr>
<tr>
<td>Gender (male vs. female)</td>
<td>0. 508</td>
<td>0.254 to 1.013</td>
<td>0.055</td></tr>
<tr>
<td>LVEF (1% step)</td>
<td>0.928</td>
<td>0.898 to 0.959</td>
<td>&lt;0.001</td></tr>
<tr>
<td>Peak glycaemia (1 g/l step)</td>
<td>1.127</td>
<td>0.800 to 1.588</td>
<td>0.495</td></tr>
<tr>
<td colspan="4">Hosmer-Lemeshow goodness-of-fit χ<sup>2 </sup>= 13.64, <italic>p</italic> = 0.092. Nagelkerke R<sup>2 </sup>= 0.11.</td></tr>
</tbody>
</table>
<table-wrap-foot>
<fn id="table-fn9-1741826711400511"><p>eGFR, estimated glomerular filtration rate; ICCU, intensive cardiac care unit; LVEF, left ventricular ejection fraction; PCI, percutaneous coronary intervention; TnI, troponin I.</p></fn></table-wrap-foot>
</table-wrap></p>
</sec>
</sec>
<sec id="sec8-1741826711400511" sec-type="discussion"><title>Discussion</title>
<p>Data on the impact of sex on outcome in patients with STEMI treated with primary angioplasty are still contrasting.<sup><xref ref-type="bibr" rid="bibr1-1741826711400511">1</xref>,<xref ref-type="bibr" rid="bibr9-1741826711400511">9</xref></sup> Discrepancies may be related to differences in study design but also in gender bias in management and in age and comorbidities. In the CADILLAC Trial, women had higher mortality than men after interventional treatment for acute myocardial infarction, which the authors attributed to smaller body surface area and more comorbidities.<sup><xref ref-type="bibr" rid="bibr10-1741826711400511">10</xref></sup> On the contrary, other authors have suggested that the higher mortality seen in women after an acute myocardial infarction might be explained by less aggressive treatment,<sup><xref ref-type="bibr" rid="bibr11-1741826711400511">11</xref></sup> and, if women had access to the same quality of care as men, their survival would be the same.<sup><xref ref-type="bibr" rid="bibr3-1741826711400511">3</xref></sup> De Luca et al.<sup><xref ref-type="bibr" rid="bibr12-1741826711400511">12</xref></sup> found, in 1548 STEMI patients, that female gender was not an independent predictor of death. Similar findings were reported by Vacek et al.<sup><xref ref-type="bibr" rid="bibr13-1741826711400511">13</xref></sup> More recently De Luca et al.<sup><xref ref-type="bibr" rid="bibr14-1741826711400511">14</xref></sup> investigated sex-related differences in clinical and angiographic findings in 1662 patients with STEMI treated with primary angioplasty and IIb–IIIa glycoprotein inhibitor (the EGYPT database). They documented that female gender was associated with higher mortality rate in comparison with men, and this was mainly due to their higher clinical and angiographic risk profiles. In fact, female sex did not emerge as an independent predictor of mortality. In the KAMIR database (4037 patients), the proportion of patients who had reperfusion therapy within 12 hours from chest pain onset was lower in women.<sup><xref ref-type="bibr" rid="bibr15-1741826711400511">15</xref></sup> The authors documented that, although women have a higher in-hospital mortality than men, female gender itself is not an independent risk factor for in-hospital mortality. Similarly, in the Shanghai Acute Coronary Event (SACE) registry (1574 men and 468 women),<sup><xref ref-type="bibr" rid="bibr16-1741826711400511">16</xref></sup> despite more advanced age and clustering of risk factors in women, female patients with STEMI treated by sirolimus-eluting-stent based primary PCI had similar in-hospital and short-term clinical outcomes as their male counterparts.</p>
<p>Our investigation is an Italian single-centre registry assessing gender-differences in early outcomes of consecutive STEMI patients submitted to primary PCI over a 6-year period. Though primary PCI is equally performed in women in respect to men, longer ischaemic times, lower use of IIbIIIa glycoprotein inhibitor, and more frequent implantations of bare metal stents were observed in women. The higher in-ICCU mortality observed in women can be related to several factors. Firstly, in our series we confirmed that STEMI women are older, more hypertensive, diabetic, with neurological impairment, and with a higher incidence of chronic obstructive pulmonary disease and renal failure.<sup><xref ref-type="bibr" rid="bibr1-1741826711400511">1</xref>,<xref ref-type="bibr" rid="bibr3-1741826711400511">3</xref>,<xref ref-type="bibr" rid="bibr4-1741826711400511">4</xref></sup> Secondly, despite similar angiographic characteristics, a higher incidence of PCI failure was detectable in women, who exhibited a more severe haemodynamic derangement as inferred by the higher Killip class, the lower left ventricular ejection fraction, and, indirectly, by the higher use of inotropes. Besides, as previously reported,<sup><xref ref-type="bibr" rid="bibr17-1741826711400511">17</xref>,<xref ref-type="bibr" rid="bibr18-1741826711400511">18</xref></sup> in our population the incidence of major bleedings and blood transfusion was higher in women who showed a lower admission haemoglobin values.</p>
<p>For the first time, we observed that women, when compared with men, showed different metabolic and inflammatory responses to acute myocardial ischaemia as indicated by higher values of admission glycaemia (in the lack of differences in glycated haemoglobin) and of fibrinogen and ESR. Interestingly, a worse glycaemic control was observed in females during ICCU stay, as indicated by the higher peak glucose values. Recently, we observed in 252 STEMI patients without previously known diabetes that the poorer in-hospital glucose control was associated with higher mortality; peak glycaemia <italic>p</italic> &gt; 180 mg/dl was associated with the highest mortality, whereas patients with peak glycaemia 140–180 mg/dl exhibited intermediate mortality rates.<sup><xref ref-type="bibr" rid="bibr15-1741826711400511">15</xref></sup></p>
<p>Data on the inter-relationship of sex and hyperglycaemia in the setting of acute coronary syndromes (ACS) are few and contrasting. In a retrospective analysis of 1575 patients with a confirmed ACS (about 30% with STEMI) and no previous diagnosis of diabetes mellitus, hyperglycaemia was a concentration-dependent predictor of long-term mortality after ACS; this predictive value was stronger in men than women. On the other hand, in the Euro Heart Survey of ACS, in women, diabetes was associated with higher risk of presenting with ST-elevation ACS, developing Q-wave myocardial infarction, and of in-hospital mortality, thus suggesting a differential effect of diabetes on the pathophysiology of ACS based on the patient’s sex.<sup><xref ref-type="bibr" rid="bibr19-1741826711400511">19</xref></sup> Differently from previous studies,<sup><xref ref-type="bibr" rid="bibr16-1741826711400511">16</xref>,<xref ref-type="bibr" rid="bibr19-1741826711400511">19</xref></sup> our investigation is prospective and it includes only STEMI patients submitted to PCI. We documented a different, gender-related, acute glucose response to myocardial ischaemia, with females showing a poorer in-hospital glycaemic control. Our data may suggest that a more intensive glucose management is needed in STEMI females.</p>
<p>A different inflammatory pattern has been described in women in respect men.<sup><xref ref-type="bibr" rid="bibr20-1741826711400511">20</xref></sup> Women have, on average, greater mean C-reactive protein measures compared with men, since the time of puberty,<sup><xref ref-type="bibr" rid="bibr21-1741826711400511">21</xref></sup> as well as a 2–50-fold greater frequency of inflammatory-mediated autoimmune diseases, such as rheumatoid arthritis or systemic lupus erythaematosus.<sup><xref ref-type="bibr" rid="bibr22-1741826711400511">22</xref></sup> Indeed, in women the relative risk of future ischaemic heart disease events increases proportionally with increasing levels of hs-C-reactive protein, acting synergistically with other risk factors.<sup><xref ref-type="bibr" rid="bibr20-1741826711400511">20</xref></sup> Gender differences have been reported in the inflammatory response to stress in healthy individuals.<sup><xref ref-type="bibr" rid="bibr23-1741826711400511">23</xref></sup> After acute psychological stress, men showed a significant decrease in cytokine production from before to immediately following the stressor, whereas women showed no change across this period. Menopausal status partially accounted for these gender differences, with postmenopausal women displaying greater increases in interleukin 6 and tumour necrosis factor α production from baseline-to-post task when compared to men. Similarly, in our population, STEMI women showed an increase inflammatory response to acute myocardial ischaemia which can be partly related to their older age.</p>
<p>In conclusion, according to our data, STEMI women show not only a different risk profile (older age, comorbidities, lower haemoglobin values), but also a different gender-related metabolic and inflammatory responses to acute myocardial ischaemia in respect to men. All these factors can account for the higher in-ICCU mortality in women and strongly suggest that STEMI women deserve more intensive care due to a more severe haemodynamic derangement (as indicated by the higher use of inotropes, diuretics, and non-invasive ventilation) and to a more serious metabolic impairment (as inferred by higher glucose values).</p>
</sec>
</body>
<back>
<sec id="sec9-1741826711400511"><title>Funding</title>
<p>This research received no specific grant from any funding agency in the public, commercial, or not-for-profit sectors.</p>
</sec>
<ref-list>
<title>References</title>
<ref id="bibr1-1741826711400511"><label>1</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Sjauw</surname><given-names>KD</given-names></name><name><surname>Stegenga</surname><given-names>NK</given-names></name><name><surname>Engström</surname><given-names>AE</given-names></name><name><surname>van der Schaaf</surname><given-names>RJ</given-names></name><name><surname>Vis</surname><given-names>MM</given-names></name><name><surname>Macleod</surname><given-names>A</given-names></name><etal/></person-group>. <article-title>The influence of gender on short- and long-term outcome after primary PCI and delivered medical care for ST-segment elevation myocardial infarction</article-title>. <source>EuroIntervention</source> <year>2010</year>; <volume>5</volume>(<issue>7</issue>): <fpage>780</fpage>–<lpage>787</lpage>.</citation></ref>
<ref id="bibr2-1741826711400511"><label>2</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Malacrida</surname><given-names>R</given-names></name><name><surname>Genoni</surname><given-names>M</given-names></name><name><surname>Maggioni</surname><given-names>AP</given-names></name><name><surname>Spataro</surname><given-names>V</given-names></name><name><surname>Parish</surname><given-names>S</given-names></name><name><surname>Palmer</surname><given-names>A</given-names></name><etal/></person-group>. <article-title>A comparison of the early outcome of acute myocardial infarction in women and men. The Third International Study of Infarct Survival Collaborative Group</article-title>. <source>N Engl J Med</source> <year>1998</year>; <volume>338</volume>(<issue>1</issue>): <fpage>8</fpage>–<lpage>14</lpage>.</citation></ref>
<ref id="bibr3-1741826711400511"><label>3</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Griffith</surname><given-names>D</given-names></name><name><surname>Hamilton</surname><given-names>K</given-names></name><name><surname>Norrie</surname><given-names>J</given-names></name><name><surname>Isles</surname><given-names>C</given-names></name></person-group>. <article-title>Early and late mortality after myocardial infarction in men and women: prospective observational study</article-title>. <source>Heart</source> <year>2005</year>; <volume>91</volume>: <fpage>305</fpage>–<lpage>307</lpage>.</citation></ref>
<ref id="bibr4-1741826711400511"><label>4</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Jneid</surname><given-names>H</given-names></name><name><surname>Fonarow</surname><given-names>GC</given-names></name><name><surname>Cannon</surname><given-names>CP</given-names></name><name><surname>Hernandez</surname><given-names>AF</given-names></name><name><surname>Palacios</surname><given-names>IF</given-names></name><name><surname>Maree</surname><given-names>AO</given-names></name><etal/></person-group><collab>Get With the Guidelines Steering Committee and Investigators</collab>. <article-title>Sex differences in medical care and early death after acute myocardial infarction</article-title>. <source>Circulation</source> <year>2008</year>; <volume>118</volume>(<issue>25</issue>): <fpage>2803</fpage>–<lpage>2810</lpage>.</citation></ref>
<ref id="bibr5-1741826711400511"><label>5</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Kushner</surname><given-names>FG</given-names></name><name><surname>Hand</surname><given-names>M</given-names></name><name><surname>Smith</surname><given-names>SC</given-names><suffix>Jr</suffix></name><name><surname>King</surname><given-names>SB</given-names><suffix>3rd</suffix></name><name><surname>Anderson</surname><given-names>JL</given-names></name><name><surname>Antman</surname><given-names>EM</given-names></name><name><surname>Bailey</surname><given-names>SR</given-names></name><etal/></person-group>. <article-title>2009 focused updates: ACC/AHA guidelines for the management of patients with ST-elevation myocardial infarction (updating the 2004 guideline and 2007 focused update) and ACC/AHA/SCAI guidelines on percutaneous coronary intervention (updating the 2005 guideline and 2007 focused update) a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines</article-title>. <source>J Am Coll Cardiol</source> <year>2009</year>; <volume>54</volume>(<issue>23</issue>): <fpage>2205</fpage>–<lpage>2241</lpage>.</citation></ref>
<ref id="bibr6-1741826711400511"><label>6</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Valente</surname><given-names>S</given-names></name><name><surname>Lazzeri</surname><given-names>C</given-names></name><name><surname>Chiostri</surname><given-names>M</given-names></name><name><surname>Giglioli</surname><given-names>C</given-names></name><name><surname>Sori</surname><given-names>A</given-names></name><name><surname>Tigli</surname><given-names>S</given-names></name><etal/></person-group>. <article-title>NT-proBNP on admission for early risk stratification in STEMI patients submitted to PCI. Relation with extension of STEMI and inflammatory markers</article-title>. <source>Int J Cardiol</source> <year>2009</year>; <volume>132</volume>(<issue>1</issue>): <fpage>84</fpage>–<lpage>89</lpage>.</citation></ref>
<ref id="bibr7-1741826711400511"><label>7</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Lazzeri</surname><given-names>C</given-names></name><name><surname>Valente</surname><given-names>S</given-names></name><name><surname>Chiostri</surname><given-names>M</given-names></name><name><surname>Picariello</surname><given-names>C</given-names></name><name><surname>Gensini</surname><given-names>GF</given-names></name></person-group>. <article-title>In hospital peak glycemia and prognosis in STEMI patients without previously known diabetes</article-title>. <source>Eur J Card Prev Rehab</source> <year>2010</year>; <volume>17</volume>(<issue>4</issue>): <fpage>419</fpage>–<lpage>423</lpage>.</citation></ref>
<ref id="bibr8-1741826711400511"><label>8</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Chesebro</surname><given-names>JH</given-names></name><name><surname>Knatterud</surname><given-names>G</given-names></name><name><surname>Roberts</surname><given-names>R</given-names></name><name><surname>Borer</surname><given-names>J</given-names></name><name><surname>Cohen</surname><given-names>LS</given-names></name><name><surname>Dalen</surname><given-names>J</given-names></name><etal/></person-group>. <article-title>Thrombolysis In Myocardial Infarction (TIMI) trial, phase I: a comparison between intravenous tissue plasminogen activator and intravenous streptokinase. Clinical findings through hospital discharge</article-title>. <source>Circulation</source> <year>1987</year>; <volume>76</volume>: <fpage>142</fpage>–<lpage>154</lpage>.</citation></ref>
<ref id="bibr9-1741826711400511"><label>9</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Bufe</surname><given-names>A</given-names></name><name><surname>Wolfertz</surname><given-names>J</given-names></name><name><surname>Dinh</surname><given-names>W</given-names></name><name><surname>Bansemir</surname><given-names>L</given-names></name><name><surname>Koehler</surname><given-names>T</given-names></name><name><surname>Haltern</surname><given-names>G</given-names></name><etal/></person-group>. <article-title>Gender-based differences in long-term outcome after ST-elevation myocardial infarction in patients treated with percutaneous coronary intervention</article-title>. <source>J Womens Health (Larchmt)</source> <year>2010</year>; <volume>19</volume>(<issue>3</issue>): <fpage>471</fpage>–<lpage>475</lpage>.</citation></ref>
<ref id="bibr10-1741826711400511"><label>10</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Lansky</surname><given-names>AJ</given-names></name><name><surname>Pietras</surname><given-names>C</given-names></name><name><surname>Costa</surname><given-names>RA</given-names></name><name><surname>Tsuchiya</surname><given-names>Y</given-names></name><name><surname>Brodie</surname><given-names>BR</given-names></name><name><surname>Cox</surname><given-names>DA</given-names></name><etal/></person-group>. <article-title>Gender differences in outcomes after primary angioplasty versus primary stenting with and without abciximab for acute myocardial infarction: results of the Controlled Abciximab and Device Investigation to Lower Late Angioplasty Complications (CADILLAC) trial</article-title>. <source>Circulation</source> <year>2005</year>; <volume>111</volume>(<issue>13</issue>): <fpage>1611</fpage>–<lpage>1618</lpage>.</citation></ref>
<ref id="bibr11-1741826711400511"><label>11</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Mosca</surname><given-names>L</given-names></name><name><surname>Appel</surname><given-names>LJ</given-names></name><name><surname>Benjamin</surname><given-names>EJ</given-names></name><name><surname>Berra</surname><given-names>K</given-names></name><name><surname>Chandra-Strobos</surname><given-names>N</given-names></name><name><surname>Fabunmi</surname><given-names>RP</given-names></name><etal/></person-group><collab>American Heart Association</collab>. <article-title>Evidence-based guidelines for cardiovascular disease prevention in women</article-title>. <source>Circulation</source> <year>2004</year>; <volume>109</volume>(<issue>5</issue>): <fpage>672</fpage>–<lpage>693</lpage>.</citation></ref>
<ref id="bibr12-1741826711400511"><label>12</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>De Luca</surname><given-names>G</given-names></name><name><surname>Suryapranata</surname><given-names>H</given-names></name><name><surname>Dambrink</surname><given-names>JH</given-names></name><name><surname>Ottervanger</surname><given-names>JP</given-names></name><name><surname>van’t Hof</surname><given-names>AW</given-names></name><name><surname>Zijlstra</surname><given-names>F</given-names></name><etal/></person-group>. <article-title>Sex-related differences in outcome after ST-segment elevation myocardial infarction treated by primary angioplasty: data from the Zwolle myocardial infarction study</article-title>. <source>Am Heart J</source> <year>2004</year>; <volume>148</volume>(<issue>5</issue>): <fpage>852</fpage>–<lpage>856</lpage>.</citation></ref>
<ref id="bibr13-1741826711400511"><label>13</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Vacek</surname><given-names>JL</given-names></name><name><surname>Rosamond</surname><given-names>TL</given-names></name><name><surname>Kramer</surname><given-names>PH</given-names></name><name><surname>Crouse</surname><given-names>LJ</given-names></name><name><surname>Porter</surname><given-names>CB</given-names></name><name><surname>Robuck</surname><given-names>OW</given-names></name><etal/></person-group>. <article-title>Sex-related differences in patients undergoing direct angioplasty for acute myocardial infarction</article-title>. <source>Am Heart J</source> <year>1993</year>; <volume>126</volume>(<issue>3 Pt 1</issue>): <fpage>521</fpage>–<lpage>525</lpage>.</citation></ref>
<ref id="bibr14-1741826711400511"><label>14</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>De Luca</surname><given-names>G</given-names></name><name><surname>Gibson</surname><given-names>CM</given-names></name><name><surname>Gyöngyösi</surname><given-names>M</given-names></name><name><surname>Zeymer</surname><given-names>U</given-names></name><name><surname>Dudek</surname><given-names>D</given-names></name><name><surname>Arntz</surname><given-names>HR</given-names></name><etal/></person-group>. <article-title>Gender-related differences in outcome after ST-segment elevation myocardial infarction treated by primary angioplasty and glycoprotein IIb-IIIa inhibitors: insights from the EGYPT cooperation</article-title>. <source>J Thromb Thrombolysis </source> <year>2010</year>; <volume>30</volume>(<issue>3</issue>): <fpage>342</fpage>–<lpage>346</lpage>.</citation></ref>
<ref id="bibr15-1741826711400511"><label>15</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Park</surname><given-names>JS</given-names></name><name><surname>Kim</surname><given-names>YJ</given-names></name><name><surname>Shin</surname><given-names>DG</given-names></name><name><surname>Jeong</surname><given-names>MH</given-names></name><name><surname>Ahn</surname><given-names>YK</given-names></name><name><surname>Chung</surname><given-names>WS</given-names></name><etal/></person-group><collab>for the Korean Acute Myocardial Infarction Registry (KAMIR) Group</collab>. <article-title>Gender differences in clinical features and in-hospital outcomes in ST-segment elevation acute myocardial infarction: from the Korean Acute Myocardial Infarction Registry (KAMIR) study</article-title>. <source>Clin Cardiol</source> <year>2010</year>; <volume>33</volume>(<issue>8</issue>): <fpage>E1</fpage>–<lpage>E6</lpage>.</citation></ref>
<ref id="bibr16-1741826711400511"><label>16</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Zhang</surname><given-names>Q</given-names></name><name><surname>Qiu</surname><given-names>JP</given-names></name><name><surname>Zhang</surname><given-names>RY</given-names></name><name><surname>Li</surname><given-names>YG</given-names></name><name><surname>He</surname><given-names>B</given-names></name><name><surname>Jin</surname><given-names>HG</given-names></name><etal/></person-group>. <article-title>Absence of gender disparity in short-term clinical outcomes in patients with acute ST-segment elevation myocardial infarction undergoing sirolimus-eluting stent based primary coronary intervention: a report from Shanghai Acute Coronary Event (SACE) Registry</article-title>. <source>Chin Med J (Engl)</source> <year>2010</year>; <volume>123</volume>(<issue>7</issue>): <fpage>782</fpage>–<lpage>788</lpage>.</citation></ref>
<ref id="bibr17-1741826711400511"><label>17</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Feit</surname><given-names>F</given-names></name><name><surname>Voeltz</surname><given-names>MD</given-names></name><name><surname>Attubato</surname><given-names>MJ</given-names></name><name><surname>Lincoff</surname><given-names>MA</given-names></name><name><surname>Chew</surname><given-names>DP</given-names></name><name><surname>Bittl</surname><given-names>JA</given-names></name><etal/></person-group>. <article-title>Predictors and impact of major hemorrhage on mortality following percutaneous coronary intervention from the REPLACE-2 trial</article-title>. <source>Am J Cardiol</source> <year>2007</year>; <volume>100</volume>: <fpage>1364</fpage>–<lpage>1369</lpage>.</citation></ref>
<ref id="bibr18-1741826711400511"><label>18</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Moukian</surname><given-names>SV</given-names></name></person-group>. <article-title>Predictors and impact of bleeding complications in percutaneous coronary intervention, acute coronary syndromes, and ST-segment elevation myocardial infarction</article-title>. <source>Am J Cardiol</source> <year>2009</year>; <volume>104</volume>(<issue>suppl</issue>): <fpage>9C</fpage>–<lpage>15C</lpage>.</citation></ref>
<ref id="bibr19-1741826711400511"><label>19</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Dotevall</surname><given-names>A</given-names></name><name><surname>Hasdai</surname><given-names>D</given-names></name><name><surname>Wallentin</surname><given-names>L</given-names></name><name><surname>Battler</surname><given-names>A</given-names></name><name><surname>Rosengren</surname><given-names>A</given-names></name></person-group>. <article-title>Diabetes mellitus: clinical presentation and outcome in men and women with acute coronary syndromes. Data from the Euro Heart Survey ACS</article-title>. <source>Diabet Med</source> <year>2005</year>; <volume>22</volume>(<issue>11</issue>): <fpage>1542</fpage>–<lpage>1550</lpage>.</citation></ref>
<ref id="bibr20-1741826711400511"><label>20</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Shaw</surname><given-names>LJ</given-names></name><name><surname>Bugiardini</surname><given-names>R</given-names></name><name><surname>Merz</surname><given-names>CN</given-names></name></person-group>. <article-title>Women and ischemic heart disease: evolving knowledge</article-title>. <source>J Am Coll Cardiol</source> <year>2009</year>; <volume>54</volume>(<issue>17</issue>): <fpage>1561</fpage>–<lpage>1575</lpage>.</citation></ref>
<ref id="bibr21-1741826711400511"><label>21</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Wong</surname><given-names>ND</given-names></name><name><surname>Pio</surname><given-names>J</given-names></name><name><surname>Valencia</surname><given-names>R</given-names></name><name><surname>Thakal</surname><given-names>G</given-names></name></person-group>. <article-title>Distribution of C-reactive protein and its relation to risk factors and coronary heart disease risk estimation in the National Health and Nutrition Examination Survey (NHANES) III</article-title>. <source>Prev Cardiol</source> <year>2001</year>; <volume>4</volume>(<issue>3</issue>): <fpage>109</fpage>–<lpage>114</lpage>.</citation></ref>
<ref id="bibr22-1741826711400511"><label>22</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Bessant</surname><given-names>R</given-names></name></person-group>. <article-title>Risk of coronary heart disease and stroke in a large British cohort of patients with systemic lupus erythematosus</article-title>. <source>Rheumatology</source> <year>2004</year>; <volume>43</volume>: <fpage>924</fpage>–<lpage>929</lpage>.</citation></ref>
<ref id="bibr23-1741826711400511"><label>23</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Prather</surname><given-names>AA</given-names></name><name><surname>Carroll</surname><given-names>JE</given-names></name><name><surname>Fury</surname><given-names>JM</given-names></name><name><surname>McDade</surname><given-names>KK</given-names></name><name><surname>Ross</surname><given-names>D</given-names></name><name><surname>Marsland</surname><given-names>AL</given-names></name></person-group>. <article-title>Gender differences in stimulated cytokine production following acute psychological stress</article-title>. <source>Brain Behav Immun</source> <year>2009</year>; <volume>23</volume>(<issue>5</issue>): <fpage>622</fpage>–<lpage>628</lpage>.</citation></ref>
</ref-list>
</back>
</article>